Management of multiple myeloma by Thomson, J
Multiple myeloma (MM) is a clonal disorder of terminally 
differentiated B-cells, that is plasma cells. The disease is characterised 
by a monoclonal gammanopathy, lytic bony lesions, anaemia/bone 
marrow failure and renal insufficiency.  Until recently the treatment 
of this disease remained unsatisfactory, with patients following a 
chronic progressive course.1
Over the past decade the approach to patients with MM has 
changed radically. For over 30 years no therapy was superior to 
oral melphalan and prednisone (MP).2 However, melphalan led 
to a complete remission (CR) rate of less than 10% and did not 
prolong survival beyond 3 years.
On the other hand, high-dose melphalan followed by stem cell 
rescue leads to CR rates of up to 60% and prolongs overall survival 
up to 7 years.3 Therefore high-dose therapy has become the 
treatment of choice for patients with MM world-wide.3
What is the clinical presentation of 
these patients?
Patients with MM present with various symptoms from bony 
pain to pathological fractures, symptomatic anaemia, recurrent 
infections and acute renal failure. The increased protein in the 
blood may lead to hyperviscosity (Table I).
Two medical emergencies that occur in these patients are 
hypercalcaemia secondary to the lytic bony lesions and spinal cord 
compression secondary to vertebral collapse.
The normal age at presentation of patents with MM is generally in 
the 6th - 7th decade. However, in South Africa, especially in the 
black population, patients present in their 4th decade. Therefore 
the diagnosis should be considered in any age group.
How do we make the diagnosis?
In order to make the diagnosis of MM one needs to prove the 
presence of:
•  a monoclonal protein in the serum or the urine 
•   an increase of plasma cells in the bone marrow or a plasmacytoma, 
as well as
•   one of the following: lytic lesions, anaemia, renal insufficiency or 
hypercalcaemia.1
Clinical investigations routinely requested if one suspects the 
diagnosis of MM are the following:
•  full blood count
•  renal function
•  calcium level
•  immunoglobulin levels and serum protein electrophoresis
•  beta-2 microglobulin
•  bone marrow aspiration and biopsy
•  skeletal survey 
•   MRI (to detect very small lytic bony lesions) may sometimes be 
needed.
What about staging and what is the 
expected prognosis?
Until recently, traditional staging systems such as the Durie and 
Salmon system were used for staging patients with MM.4 A more 
accurate technique called the International Staging System (ISS) 
for MM has recently been introduced after a multivariate analysis 
of over 11 000 patients worldwide.4
Three stages were defined based solely on the results of the serum 
albumin and beta-2 microglobulin (Table II).5
The ISS system also identified two parameters that predicted a 
poorer outcome: age and high-dose therapy (Table III).5
Who should be treated?
According to the international working group, patients should 
be divided into asymptomatic and symptomatic. The latter 
group consists of patients considered for a chemotherapy-based 
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Table I. Myeloma-related organ or tissue 
impairment
Criterion  Diagnositic parameter
Hypercalcaemia  Serum calcium > 2.75 mmol/l
Renal insufficiency Creatinine > 173 mmol/l
Anaemia   Hb 2 g/dl below the lower limit  
   of normal, or Hb < 10 g/dl
Bony lesions  Lytic bony lesions, or osteopo- 
   rosis with compression fractures
Other associated findings Symptomatic hyperviscosity,  
   amyloidosis, recurring bacterial  
   infections
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intervention. These patients will then 
be further divided in those who either 
are or are not candidates for high-dose 
chemotherapy, followed by stem cell 
rescue. 
Age performance status and co-morbid 
disease are used to make the decision 
whether a patient is fit for high-dose 
therapy. Initially 65 was the upper age 
limit, but recently high-dose therapy has 
been delivered to patients beyond the age 
of 70 years with great success. Therefore 
most patients should be evaluated by a 
specialist haematologist or oncologist 
before they are considered unsuitable for 
high-dose therapy, as this is currently the 
only therapy that prolongs survival.
What therapy should be 
given?
Patients who are candidates for high-dose 
therapy followed by stem cell rescue will 
receive induction therapy with high-dose 
dexamethasone combined with either 
chemotherapy agents such as vincristine, 
adriamycin and cyclophosphamide or with 
thalidomide, or dexamethasone could be 
given alone. 
Currently the most active combination 
is dexamethasone combined with 
thalidomide, with response rates of up 
to 90%.6 New agents called proteosome 
inhibitors are very promising induction 
therapy agents, but they are currently still 
under investigation in various clinical 
trials as first-line therapy.
After around 4 months of induction 
therapy patients will undergo high-dose 
therapy followed by stem cell rescue. 
It is important to realise that while 
complete remission prior to stem cell 
harvesting would be preferred this is often 
not the case and not mandatory for the 
treatment plan to continue.  Most patients 
will only have a partial response to the 
induction chemotherapy.
The next step in the treatment plan is an 
autologous stem cell harvest which can be 
done by the combination of chemotherapy 
and growth factors or by growth factors 
alone. The stem cells are harvested via 
an apheresis machine.  Most physicians 
will perform a stem cell harvest large 
enough to be split into two aliquots in 
order to provide stem cells for two stem 
cell transplants. The stem cells are then 
cryopreserved for further use.
The patients then receive high-dose 
therapy with melphalan in varying doses, 
depending on the patient’s age. Melphalan 
is usually used as single agent as it is a 
very active agent in myeloma therapy and 
several trials have proven its efficacy with 
limited toxicity.3
Twenty-four hours after the melphalan dose 
the autologous stem cells are reinfused. 
Melphalan has an extremely short half-life 
and therefore the cryopreserved stem cells 
will not be harmed by the melphalan. 
This form of transplantation has limited 
toxicity, with limited cytopenia and a 
treatment-related mortality of less than 
5% in most centres, even in the elderly 
population. It may be performed on an 
outpatient basis and this is often the 
practice in the international arena.
With this procedure patients achieve 
complete remission rates of up to 50% 
and if a patient does not attain remission 
after the first procedure the procedure will 
be repeated at ± 6 months, even further 
improving complete remission rates and 
prolonging overall survival.3
After the stem cell transplants all patients 
will be placed on maintenance thalidomide 
for an additional 2 years if they can tolerate 
the therapy.3
When patients relapse or progress the 
newer agents are given as they have been 
proven to be effective in relapsed refractory 
patients. The proteosome inhibitors are 
particularly effective in this group of 
patients.
Patients who present in their 4th 
and 5th decade
Although high-dose therapy with 
melphalan increases complete remission 
rates and overall survival, most patients will 
still relapse over time and die from MM. 
Therefore young patients should always 
be considered for an allogeneic stem cell 
transplant from a HLA-identical sibling, 
as this is the only curative treatment for 
MM at the moment.
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The disease is characterised by a 
monoclonal gammanopathy, lytic bony 
lesions, anaemia/bone marrow failure 
and renal insufficiency.
Age performance status and co-morbid 
disease are used to make the decision 
whether a patient is fit for high-dose 
therapy.
Table II. International staging system for MM
Stage  Criteria    Median overall survival
I  Serum B2 microglobulin < 3.5 g/dl             62 months
II  Neither stage I or stage III              44 months
III  Serum B2 microglobulin > 5.5 mg/l             29 months
Table III. Age, chemotherapy, and the international prognostic staging 
sytem for MM
  Median overall survival  Median overall survival 
Stage  Age > 65 years   Age < 65 years
I              69 months               47 months
II              50 months               37 months
III              33 months               24 months
      Median overall  survival 
  Median overall survival with without high-dose  
Stage  high-dose chemotherapy  chemotherapy
I              111 months               55 months
II              66 months               40 months
III              45 months               25 months
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Patients who are not candidates 
for high-dose therapy
As little as 2 years ago there was general 
agreement that the standard of care 
for patients who were not eligible 
for transplantation, and yet needed 
chemotherapy, was MP. Recently, various 
randomised trials have shown that, 
with the addition of thalidomide to the 
combination of MP, complete remission 
rates increase dramatically and overall 
survival is prolonged.7 One study even 
showed that this combination is superior 
to stem cell transplantation.
Unfortunately this combination is not 
without increased toxicity and patients 
should be placed on anticoagulation due to 
a high incidence of thrombotic episodes. 
None the less most experts will agree that 
MP plus thalidomide is the treatment of 
choice for patients who are not candidates 
for stem cell transplant. 
Other combinations currently under 
investigation include combining MP with 
the proteosome inhibitors.
Conclusion
Anyone who has treated patients with MM 
will agree that the attainment of complete 
remission translates into excellent quality 
of life.  Patients achieving sustained 
remission or good partial remission are 
asymptomatic for years. They return to 
their normal daily activities, lytic bony 
lesions resolve and chronic infections 
generally clear. 
Therefore world-wide the goal of the 
treatment of MM has become the 
attainment of complete remission. 
Thankfully, with high-dose therapy and 
the new agents like thalidomide and the 
proteosome inhibitors we are obtaining 
that goal in the majority of our patients. 
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In a nutshell 
•   Multiple myeloma has a chronic pro-
gressive course if not adequately treat-
ed.
•   Standard treatment with melphalan 
and prednisone is inferior to current 
therapies.
•   Thalidomide combined with dexa-
methasone is the treatment of choice 
for induction therapy.
•   High-dose melphalan with stem cell 
rescue induces high complete remis-
sion rates and prolongs overall sur-
vival.
•   Maintenance thalidomide should be 
given post stem cell transplant.
•   Proteosome inhibitors are currently 
reserved for the relapsed refractory 
patients.
•   Patients who do not qualify for stem 
cell transplant should receive melpha-
lan and prednisone combined with 
thalidomide.
•   Complete remission should be the goal 
of therapy.
Currently the most active combination 
is dexamethasone combined with 
thalidomide, with response rates of up 
to 90%.
Therefore world-wide the goal of the 
treatment of MM has become the 
attainment of complete remission. 
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